| Today’s Big NewsJul 10, 2025 |
| By Gabrielle Masson The FDA has released an "initial batch" of more than 200 complete response letters (CRLs) in efforts to boost transparency. |
|
|
|
By Nick Paul Taylor AbbVie is paying Ichnos Glenmark Innovation $700 million upfront for a next-generation rival to Johnson & Johnson’s Tecvayli, positioning the Big Pharma to advance a new option for multiple myeloma patients. |
By James Waldron AZ ended work on the orexin 1 receptor antagonist in November after a phase 2 study identified a “potential drug-drug interaction" with the widely used antifungal itraconazole. |
Sponsored by SAP and Answerthink Leaders discuss how built-in best practices and automation streamline growth for lean life sciences teams |
|
| Is your process truly scalable, efficient and validation-ready?Can your supply chain and manufacturing scale flex as your needs evolve?Do you have the manufacturing capacity to deliver when demand takes off? Speak with Lonza’s experts and get answers that drive smarter decisions today.
|
|
By James Waldron Analysts are keeping the faith in Ultragenyx’s brittle bone disease medicine despite the monoclonal antibody failing to score an early outright win in an ongoing phase 3 trial. |
By James Waldron Nuclidium has raised 79 million Swiss francs ($99 million) as the Swiss and German biotech looks to continue the clinical journey of its copper-based radiopharmaceutical diagnostic and therapeutic offering. |
By Gabrielle Masson,Darren Incorvaia As always, if you know of layoffs occurring at a biotech, please reach out to the Fierce Biotech editorial team. |
By Darren Incorvaia Scientists have identified a new class of compounds capable of partially clearing the tropical parasite that causes Chagas disease out of mice, suggesting the molecular group could serve as a source of new treatments for one of the deadliest parasitic infections in the world. |
By Gabrielle Masson,Darren Incorvaia,James Waldron The Fierce Biotech Fundraising Tracker records venture capital rounds of $50 million or more secured by biotechs. |
By Conor Hale The company said its pilot program completed its first patient procedure that delivered the hypertension therapy to the renal arteries as well as the vessels feeding the liver. |
By Heather Landi The office of HHS Secretary Robert F. Kennedy Jr. abruptly called off a meeting of the U.S. Preventive Services Task Force scheduled for Thursday, as many healthcare experts are concerned about potential political interference that could sideline independent experts. |
Fierce podcastsDon’t miss an episode |
| | In this episode of "Podnosis," we explore why some employers are turning to value-based specialty care as a strategy to control costs and improve care quality. |
|
|---|
|
|
|
Thursday, July 22, 2025 | 10am ET / 7am PT Join us to take an exciting look at the forefront of REMS transformation. Learn how leading technology, integrated strategies and operational excellence are redefining what’s possible. Gain the insights you need to reduce complexity, enhance compliance and deliver more value across the REMS lifecycle. Register now.
|
|
| WhitepaperThis white paper outlines how we apply industry-backed practices and proprietary technologies to proactively safeguard sterility and performance. Sponsored by: Lonza |
| WhitepaperPresented by Blue Matter, strategic consultants in the life sciences Sponsored by Blue Matter Consulting |
| Executive SummaryBiotech innovation doesn’t slow down—and neither should your lab partner. This brief outlines how early scientific engagement, operational transparency, and integrated global lab services help reduce risk, stay on schedule, and deliver results. Whether you're navigating your first trial or scaling a growing pipeline, see how a purpose-built lab model can help you move smarter and faster. Sponsored by: IQVIA Laboratories |
| |
|
